Bone Biologics Business Summary

Bone Biologics Corp (BBLG) is a pre-commercial, clinical-stage biotechnology company specializing in the development of orthobiologic products for the multi-billion dollar spinal fusion, trauma, and osteoporosis markets. The company operates under a research and development business model, currently generating zero revenue from product sales and sustaining operations through strategic capital raises, such as its $5.0 million public offering in mid-2025 and subsequent warrant exercises. Its primary business segment is centered on its lead product candidate, NB1, a combination of the proprietary recombinant human protein rhNELL-1 and demineralized bone matrix (DBM) designed to provide target-specific control over bone regeneration. Positioned as a small-cap innovator in the medical equipment sector, Bone Biologics competes directly with firms such as Predictive Oncology (POAI), Intelligent Bio Solutions (INBS), and Inspira Technologies (IINN), differentiating itself through an exclusive worldwide license for the NELL-1 protein technology from the UCLA Technology Development Group. Founded in 2004 by a consortium of UCLA professors—including Dr. Xinli Zhang, Dr. Kang Ting, and Dr. Chia Soo—and a USC surgeon, the company is anchored by a leadership team with deep med-tech and financial pedigree. President and CEO Jeffrey Frelick, who assumed the role in 2019, brings over 25 years of industry experience and a 15-year tenure as a Wall Street analyst at firms like Lazard and Canaccord Genuity. The executive team includes CFO Deina Walsh, a certified public accountant with over a decade of service to the firm, and R&D Consultant Brent Atkinson, Ph.D., who oversees clinical progression. The company is supported by an experienced board chaired by Bruce Stroever, former CEO of the Musculoskeletal Transplant Foundation, and includes notable members such as Phillip T. Meikle and Bret Hankey, reflecting significant backing from the UCLA Regents and the Hankey Group.